Genomics

Quark and Fujisawa Broaden collaboration beyond gene discovery

Published in Gene Therapy Weekly, September 19th, 2002

Quark Biotech and Fujisawa Pharmaceutical Co., Ltd., announced that they are broadening their research collaboration beyond target gene discovery into drug discovery to treat stroke.

As part of this step forward, Quark will construct bioassays on target proteins selected by both Fujisawa and Quark and will perform high-throughput screening of the chemical libraries based on the bioassays developed. Quark will also continue the gene discovery and target validation program set forth under the original agreement.

Fujisawa has increased the annual research funding to Quark to cover the additional research program. Using Quark's technologies and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry